NanoLIPID™ - Innovative Lipid Systems for Enhanced Bioavailability of Drugs: Preclinical Proof of Concept

Purpose and goal

The project aims to achieve preclinical proof of concept for Emulsi Biotech’s NanoLIPID™ platform - a novel self-assembling lipid system designed to enhance oral bioavailability of peptides and other challenging drug molecules. The goal is to validate formulation stability, in-vitro release, and structural behaviour in gastrointestinal conditions, forming the basis for in-vivo studies and pharma partnerships.

Expected effects and result

Expected results include experimental validation that NanoLIPID™ forms stable liquid-crystalline nanostructures in GI-like media, protects semaglutide, and enables controlled release with preserved activity. Pilot PK data are expected to show improved oral uptake versus controls. Effects: a de-risked, partner-ready platform, accelerated licensing discussions, and a path toward safer, needle-free peptide therapeutics.

Planned approach and implementation

The project will proceed through three work packages: (1) formulation development of semaglutide-loaded NanoLIPID™, (2) in vitro release and activity testing under GI-like conditions, and (3) an in vivo pilot PK study with Truly Labs AB. Results from each stage will guide the next, ensuring systematic validation. Progress will be monitored through milestones, internal reviews, and partner input to secure robust, translatable outcomes.